Royalty Pharma will pay up to $2 billion to Revolution Medicines to support the development and sales of an experimental drug ...

Revolution Medicines and Summit Therapeutics entered into a clinical collaboration in multiple solid-tumor settings to evaluate their respective treatments in combination with each other. Redwood City ...

Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. See ...

Revolution Medicines has partnered Royalty Pharma for $2bn in flexible funding to support the independent worldwide development and commercialisation strategy of its renin-angiotensin system (RAS) ...

Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025. REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc ...

Taking an unconventional path to market for its targeted therapies for RAS-addicted cancers, Revolution Medicines Inc. secured access to $2 billion in capital to build its own global commercial ...

A high-level overview of Revolution Medicines, Inc. (RVMD) stock. View (RVMD) real-time stock price, chart, news, analysis, analyst reviews and more.

Learn about the executive team and board of directors at Revolution Medicines Inc Ordinary Shares (RVMD:XNAS) and review their bios and compensation over the latest fiscal years.

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...